Focus on Lipids Care

Back to articles

Ezetimibe/simvastatin: Cancer risk not ruled out



An analysis of three clinical trials involving more than 20,000 patients concludes that there is no convincing evidence supporting a link between ezetimibe/simvastatin (Vytorin—Merck; Schering-Plough) and cancer risk; however, some clinicians are not convinced and continue to express concern about the safety of the drug.


Rossebø AB et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359:1343–56.

Peto R et al. Analyses of cancer data from three ezetimibe trials [letter]. N Engl J Med. 2008;360:86–7.

Drazen JM et al. Ezetimibe and cancer: an uncertain association. N Engl J Med. 2008;359:1398–9.